Galecto Announces First Patient Enrolled in Phase II Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC

Galecto, Inc. announced that the first patient has been enrolled in the Phase IIa GALLANT-1 trial. GALLANT-1 was designed to study the combination of GB1211, Galecto’s oral small molecule galectin-3 inhibitor, with Roche’s PD-L1 checkpoint inhibitor, atezolizumab, for the first-line treatment of NSCLC.